{
  "validation_date": "2026-01-25",
  "total_predictions_validated": 20,
  "precision": 0.20,
  "validated_predictions": [
    {
      "drug": "Pembrolizumab",
      "disease": "Invasive Breast Carcinoma",
      "status": "FDA-Approved",
      "evidence": "FDA approved 2020-2021 for TNBC (KEYNOTE-522)",
      "recommendation": "Ground truth gap - add to known pairs"
    },
    {
      "drug": "Ravulizumab",
      "disease": "Asthma",
      "status": "Research Supported",
      "evidence": "Eculizumab proof-of-concept trial, C5/eosinophil mechanism",
      "recommendation": "Phase II trial in severe eosinophilic asthma"
    },
    {
      "drug": "Nimotuzumab",
      "disease": "Psoriasis",
      "status": "Research Supported",
      "evidence": "EGFR overexpressed in psoriasis, case reports with cetuximab",
      "recommendation": "Phase II trial - safer than cetuximab for skin"
    },
    {
      "drug": "Alirocumab",
      "disease": "Psoriasis",
      "status": "Research Supported",
      "evidence": "Mendelian Randomization p<0.003, replicated in FinnGen",
      "recommendation": "Prevention study in high-risk patients"
    },
    {
      "drug": "Brolucizumab",
      "disease": "Psoriasis",
      "status": "Research Supported",
      "evidence": "Anti-VEGF rationale, bevacizumab case reports",
      "recommendation": "Topical formulation needed - intravitreal not suitable"
    }
  ],
  "false_positives": [
    {
      "drug": "Reslizumab",
      "disease": "Ulcerative Colitis",
      "reason": "Anti-IL-5 class fails clinically despite reducing eosinophils",
      "filter_added": true
    },
    {
      "drug": "Reslizumab",
      "disease": "Psoriasis",
      "reason": "Anti-IL-5 class fails clinically",
      "filter_added": true
    },
    {
      "drug": "Reslizumab",
      "disease": "Multiple Sclerosis",
      "reason": "No eosinophil role in MS pathogenesis",
      "filter_added": true
    },
    {
      "drug": "Brolucizumab",
      "disease": "Multiple Sclerosis",
      "reason": "Intravitreal formulation, safety concerns in MS patients",
      "filter_added": true
    },
    {
      "drug": "Brolucizumab",
      "disease": "Ulcerative Colitis",
      "reason": "Intravitreal formulation not suitable for systemic disease",
      "filter_added": true
    },
    {
      "drug": "Mepolizumab",
      "disease": "Psoriasis",
      "reason": "Anti-IL-5 failed in atopic dermatitis - same class failure",
      "filter_added": true
    },
    {
      "drug": "Aducanumab",
      "disease": "Psoriasis",
      "reason": "Amyloid-beta unrelated to psoriasis; drug discontinued Jan 2024",
      "filter_added": true
    },
    {
      "drug": "Romosozumab",
      "disease": "Multiple Sclerosis",
      "reason": "Sclerostin has no role in MS; black box CV warning",
      "filter_added": false
    },
    {
      "drug": "Bectumomab",
      "disease": "Psoriasis",
      "reason": "B-cell depletion paradoxically induces psoriasis",
      "filter_added": true
    },
    {
      "drug": "Lexatumumab",
      "disease": "Ulcerative Colitis",
      "reason": "TRAIL agonism worsens epithelial damage; drug discontinued",
      "filter_added": true
    },
    {
      "drug": "Lexatumumab",
      "disease": "Psoriasis",
      "reason": "TRAIL agonism worsens psoriasis; drug discontinued",
      "filter_added": true
    },
    {
      "drug": "Volociximab",
      "disease": "Multiple Sclerosis",
      "reason": "α5β1 integrin is PROTECTIVE in MS - inhibiting worsens disease",
      "filter_added": true
    },
    {
      "drug": "Fontolizumab",
      "disease": "Multiple Sclerosis",
      "reason": "Discontinued drug; complex IFN-γ biology",
      "filter_added": true
    },
    {
      "drug": "Fontolizumab",
      "disease": "Ulcerative Colitis",
      "reason": "UC is Th2-like, not Th1 - wrong immunological pathway",
      "filter_added": true
    },
    {
      "drug": "Abciximab",
      "disease": "Multiple Sclerosis",
      "reason": "Platelet pathway valid but drug impractical (IV-only, bleeding risk)",
      "filter_added": false
    }
  ],
  "new_filter_rules_added": [
    "DISCONTINUED_DRUG_PATTERNS: aducanumab, lexatumumab, fontolizumab, volociximab, bectumomab",
    "ANTI_IL5_PATTERNS + ANTI_IL5_EXCLUDED_DISEASES: reslizumab, mepolizumab, benralizumab for psoriasis/UC/MS",
    "INTRAVITREAL_DRUG_PATTERNS + SYSTEMIC_DISEASES: brolucizumab, ranibizumab for systemic diseases",
    "BCELL_DEPLETING_PATTERNS for psoriasis: rituximab, ocrelizumab, ofatumumab, bectumomab",
    "TRAIL_AGONIST_PATTERNS for inflammatory diseases: lexatumumab, mapatumumab, conatumumab",
    "FAILED_PHASE3_COMBINATIONS: fontolizumab for UC, volociximab for MS"
  ],
  "key_learnings": [
    "Anti-IL-5 is a consistent false positive - reduces eosinophils but fails clinically",
    "Drug formulation matters - intravitreal drugs wrong for systemic diseases",
    "Mechanism can be opposite - volociximab inhibits protective α5β1 in MS",
    "B-cell depletion paradox - rituximab induces psoriasis",
    "Th1 vs Th2 distinction - Crohn's (Th1) vs UC (Th2) have different immunology",
    "20% validation rate for top predictions with 95%+ ML confidence"
  ]
}
